S&P 500 Healthcare Sector SEC Filings — June 01, 2026

01-06-2026

Lucid Group, Inc. announced that Silvio Napoli has assumed the role of CEO effective June 1, 2026, following a leadership transition previously announced on April 14. Marc Winterhoff, who served as Interim CEO, has resumed his role as Chief Operating Officer and will report to Napoli. The new CEO emphasized a focus on strengthening customer engagement, cost competitiveness, and streamlining operations.

• · Silvio Napoli was previously announced as incoming CEO on April 14, 2026.
• · Napoli most recently served as Chairman and CEO of Schindler Group, bringing experience in global operations and technology-driven businesses.
• · Marc Winterhoff had served as Interim CEO before resuming his role as COO.

01-06-2026

AITX announced that its subsidiary RAD scaled production, with Q1 FY27 hardware device shipments exceeding 100 units. The company issued a press release on June 1, 2026, highlighting this milestone. No financial figures or period-over-period comparisons were provided in the filing.

• · The press release is titled 'AITX’s RAD Scales Production as Q1 FY27 Shipments Exceed 100 Hardware Devices'.
• · The filing is an 8-K under Items 8.01 and 9.01, and the press release is attached as Exhibit 99.1.
• · The company's principal executive offices are located at 10800 Galaxie Avenue, Ferndale, MI 48220.

01-06-2026

News Corp filed an 8-K on June 1, 2026, disclosing that it provided daily repurchase transaction information to the Australian Securities Exchange (ASX) under its $1 billion stock repurchase program. The filing includes forward-looking statements regarding the company's intent to repurchase Class A and Class B common stock from time to time.

• · The repurchase program covers both Class A common stock (ticker NWSA) and Class B common stock (ticker NWS).
• · Disclosure to ASX is required on a daily basis under ASX rules.
• · The company also discloses repurchase information in quarterly and annual reports.

01-06-2026

Humana Inc. reaffirmed its FY 2026 guidance of at least $8.36 GAAP diluted EPS or at least $9.00 adjusted EPS during investor meetings from June 1-30, 2026. The guidance is consistent with the April 29, 2026 press release. No changes to adjusted EPS guidance are expected, but GAAP EPS may change due to ongoing strategic initiatives.

• · The guidance reaffirmation covers meetings from June 1 to June 30, 2026.
• · Adjusted EPS excludes amortization of intangibles ($0.30), put/call valuation adjustments (-$0.28), value creation initiatives ($0.81), and cumulative net tax impact (-$0.19).
• · GAAP EPS guidance may change due to ongoing value creation and other strategic initiatives, while adjusted EPS guidance is not expected to change.

01-06-2026

Science Applications International Corp (SAIC) announced the departure of Srinivas Attili, Executive Vice President, Civilian Business Group, effective May 29, 2026, with his final departure on or about June 12, 2026. The departure is in connection with an internal reorganization. Mr. Attili will receive severance compensation under the company's Executive Severance, Change in Control and Retirement Policy, subject to a release of claims and a two-year non-compete agreement. No financial figures or period-over-period comparisons are provided in this filing.

• · Mr. Attili stepped down from his role on May 29, 2026, and will depart the company on or about June 12, 2026.
• · Severance compensation is pursuant to Section 5 of the company's Executive Severance, Change in Control and Retirement Policy.
• · The severance requires execution and non-revocation of a release of claims and a two-year post-employment non-compete obligation.

01-06-2026

FrontView REIT, Inc. furnished update slides in connection with NAREIT's REITweek 2026 Investor Conference on June 1, 2026. The slides, attached as Exhibit 99.1, provide an update on the company's operations and strategy. No specific financial figures or performance metrics were disclosed in the filing itself.

• · The filing is a Regulation FD disclosure (Item 7.01) and the slides are furnished, not filed, for SEC purposes.
• · The company is an emerging growth company as defined under SEC rules.
• · The slides were released for the REITweek 2026 Investor Conference.

01-06-2026

Community Financial System, Inc. (CBU) announced the completion of its acquisition of ClearPoint Federal Bank & Trust by its subsidiary Community Bank, N.A. on June 1, 2026. ClearPoint is a national leader in trust administration for the death care industry with over $1.5 billion in assets under management and a historical three-year revenue CAGR of 9.7%. The transaction expands the wealth management services of Nottingham Financial Group and aligns with the company's strategic focus on durable, recurring income streams.

• · The acquisition was completed on June 1, 2026, as previously announced in an Agreement and Plan of Merger dated January 14, 2026.
• · The newly acquired business will operate as ClearPoint Trust, a division of Community Bank.
• · The press release announcing the closing is attached as Exhibit 99.1 to the 8-K filing.

01-06-2026

HCI Group, Inc. secured comprehensive reinsurance programs for its four insurance subsidiaries for the 2026-2027 treaty year (June 1, 2026 to May 31, 2027) through three fully placed reinsurance towers providing total coverage of up to $1.06 billion, $830.3 million, and $431.5 million per single event, respectively. The company expects net consolidated reinsurance premiums ceded to third parties of approximately $381.2 million, while its captive reinsurers Claddaugh and Fortex Re retain an estimated maximum combined loss of $139.8 million for the first event and $52.3 million for the second event. All private reinsurers are rated 'A-' (Excellent) or better, and the programs include coverage from the Florida Hurricane Catastrophe Fund.

• · All three reinsurance towers are fully placed and satisfy HCI's reinsurance needs for the 2026-2027 treaty year.
• · Reinsurance Tower 1 covers Homeowners Choice policies in central and southern Florida; Tower 2 covers all TypTap policies and Homeowners Choice policies outside Florida; Tower 3 covers Tailrow, CORE, and Homeowners Choice policies in northern Florida.
• · Claddaugh and Fortex Re participations remain subject to approval by the Florida Office of Insurance Regulation.
• · HCI may explore additional risk transfer instruments in the future to further enhance reinsurance protection for the 2026-2027 treaty year.
• · Reinsurance premiums are estimates based on exposure projections and subject to true-up at September 30, 2026.
• · All private reinsurers are AM Best rated 'A-' (Excellent) or better, or have fully collateralized their obligations.
• · The Florida Hurricane Catastrophe Fund agreement covers only storms designated as hurricanes by the National Hurricane Center.

01-06-2026

CVB Financial Corp. (CVBF) entered into a Third Amended and Restated Employment Agreement with CEO David A. Brager on June 1, 2026, extending his term through June 30, 2029. The agreement maintains his base salary at $966,000 and provides a target bonus of 120% of base salary, with a maximum of 180%, along with annual equity grants expected at 180% of base salary. The early renewal, originally set to expire in 2027, reflects the Board's confidence in Mr. Brager's leadership, but the extended term and enhanced severance provisions (including 2.5x pay upon change-in-control) increase the company's long-term compensation commitments.

• · Mr. Brager has been employed by the company since 2003 and served as Executive Vice President and Sales Division Manager from 2010 to 2020.
• · The agreement includes a monthly automobile allowance of $2,000 and reimbursement for one country club and one social club membership.
• · Upon death or permanent disability, all unvested options, Time RSUs, and Performance RSUs vest in full (Performance RSUs at target).
• · Severance benefits are conditioned upon execution of a release of claims in favor of the company.
• · The agreement provides for successive one-year renewal terms after June 30, 2029, unless terminated by either party.

01-06-2026

Disciplined Growth Acquisition Corporation announced the pricing of its $150 million initial public offering of 15,000,000 units at $10.00 per unit. The units consist of one Class A ordinary share and one right to receive one-fourth of a Class A ordinary share upon a future business combination. The offering is expected to close on May 28, 2026, with units trading on the NYSE under the symbol DGACU starting May 27, 2026.

• · The underwriter has a 45-day option to purchase up to an additional 2,250,000 units at the IPO price to cover over-allotments.
• · The registration statement was declared effective by the SEC on May 26, 2026.
• · The Company intends to focus its search for a business combination target in financial technology, aerospace and defense technology, clean technology, and other sectors with disruptive market opportunities.
• · The Company's management team is led by Robert Wotczak (CEO and Chairman) and Emma Dell'Acqua (CFO).

01-06-2026

Stewards, Inc. filed Amendment No. 3 to its S-1 registration statement for an IPO. The filing details executive compensation for fiscal years 2024 and 2025, including a one-time RSU recognition grant of 250,000 RSUs each to six named executives (valued at $1,275,000 per executive based on a $5.10 stock price), though these RSUs remain unvested as of December 31, 2025. The company also approved a new executive compensation program with phased implementation from 2025-2028, a Director Compensation Plan, and a leadership transition where Vincent Napolitano will become Chairman Emeritus and Shaun Quin will become CEO. However, the company is no longer actively pursuing a Nasdaq listing, and the RSUs' vesting conditions may be revised.

• · The company is no longer actively pursuing a Nasdaq listing, and the RSU vesting conditions may be revised or waived.
• · Directors were not compensated during 2024 and through Q3 2025; compensation began in Q4 2025.
• · The 2024 Equity Incentive Plan reserves 20,000,000 shares of common stock and expires August 21, 2034.
• · The new executive compensation program includes ownership guidelines (6x base salary for CEO, 5x for President, 3x for COO/CFO, 2x for other officers) and a clawback policy consistent with SEC Rule 10D-1.
• · Vincent Napolitano's salary decreased from $233,610 in 2024 to $205,432 in 2025, a decline of 12.1%.
• · Shaun Quin's salary decreased from $138,507 in 2024 to $122,030 in 2025, a decline of 11.9%.
• · Glen Steward resigned as Chief Strategy Officer effective December 1, 2025, but remains on the Board.
• · The Board will become majority-independent after Napolitano steps down.

01-06-2026

Citius Pharmaceuticals, Inc. (CTXR) announced via its subsidiary Citius Oncology that Phase 1 clinical data for LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab in recurrent or refractory gynecologic malignancies were presented at the ASCO Annual Meeting. The study showed a 24% overall response rate (ORR) among 21 efficacy-evaluable patients and a 33% ORR in endometrial cancer patients previously treated with checkpoint inhibitors, with a median progression-free survival (mPFS) of 20.5 months among the 48% achieving clinical benefit. However, the overall mPFS across all evaluable patients was only 5.8 months, and 16 serious adverse events were observed at the highest dose level, highlighting the mixed nature of the early-stage data.

• · Median duration of response (mDOR) not yet reached; only 1 of 5 partial responders had progressed at analysis.
• · Current duration of response times: 4.2–35 months, median 21.1 months.
• · Overall mPFS across all 21 evaluable patients was 5.8 months (95% CI: 2.2 – NA).
• · Maximum tolerated dose was not achieved; only 1 case of reversible Grade 3 capillary leak syndrome at highest dose level.
• · No new safety signals or Grade 3+ immune-related adverse events observed.
• · LYMPHIR is not FDA-approved for gynecologic malignancies or any solid tumor; this was an investigational use.
• · Citius Oncology provided study drug and financial support; study designed and analyzed by UPMC investigators.
• · LYMPHIR was launched in the U.S. in December 2025 for relapsed/refractory Stage I–III CTCL.

01-06-2026

Praxis Precision Medicines announced that its Phase 2/3 POWER1 study evaluating vormatrigine in patients with focal onset seizures (FOS) did not meet the primary success measure. However, the secondary 50% response rate was achieved, and seizure reduction was more pronounced on the higher 30 mg dose during the second half of the study. The company is pausing enrollment in the POWER2 study to reassess the program, while approximately 90% of patients from the vormatrigine arm transitioned to the open label extension study.

• · The POWER1 study was in highly refractory patients with focal onset seizures (FOS).
• · Vormatrigine was generally well-tolerated with adverse event-related discontinuations less than 10%.
• · The company is pausing enrollment in the POWER2 study to reassess the program and determine potential modifications.

01-06-2026

O'Reilly Automotive, Inc. announced on June 1, 2026, that its Board of Directors approved a $2.0 billion increase to its existing share repurchase program, raising the total authorization to $31.75 billion. The additional authorization is effective for a three-year period beginning June 1, 2026, with repurchases to be made through open market transactions at prevailing market prices. The company cautioned that there is no assurance as to the number of shares that will be purchased and that the program may be modified, suspended, or terminated at any time.

• · The additional $2.0 billion authorization is effective for a three-year period beginning June 1, 2026.
• · Repurchases will be made solely through open market repurchases effected through a broker dealer at prevailing market prices.
• · The company may increase, modify, renew, suspend, or terminate the program at any time without prior notice.
• · There is no assurance as to the number of shares the company will purchase, if any.

01-06-2026

LP Building Solutions (LPX) announced the retirement of Executive Vice President and CFO Alan Haughie, effective September 1, 2026, with Aaron Howald appointed as his successor. Haughie will remain in an advisory capacity through February 2027 to ensure a smooth transition. The change is part of a planned succession and does not reflect any negative financial or operational performance.

• · Alan Haughie joined LP in 2019 as Executive Vice President and CFO.
• · Aaron Howald has been with LP for 15 years, most recently as Vice President, Investor Relations and Business Development.
• · Howald holds an MBA from Indiana University Kelley School of Business and a BA in Finance and Economics from Franklin College.
• · LP operates more than 20 manufacturing facilities across North and South America.
• · The company was founded in 1972 and is headquartered in Nashville, Tennessee.

01-06-2026

Stewart Information Services Corp announced a cash dividend of $0.525 per share for Q2 2026, payable June 30, 2026 to holders of record on June 15, 2026. The dividend amount remains unchanged from the prior quarter, indicating stable shareholder returns but no growth in payout.

01-06-2026

Arrow Financial Corporation announced a joint press release with Adirondack Bancorp, Inc. on June 1, 2026, indicating a potential acquisition or merger transaction. The filing is made under Rule 425, which covers written communications related to business combinations. No financial terms or performance metrics were disclosed in this filing.

• · The filing is a Form 8-K with Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits).
• · The press release is attached as Exhibit 99.1 and is incorporated by reference.
• · The filing is made under Rule 425 of the Securities Act, indicating a business combination communication.
• · Arrow Financial Corporation is headquartered in Glens Falls, New York, and trades on NASDAQ under the symbol AROW.

01-06-2026

Citius Oncology, Inc. (CTOR) announced Phase 1 clinical data at the ASCO 2026 Annual Meeting showing that LYMPHIR in combination with pembrolizumab achieved a 24% ORR and a median PFS of 20.5 months in heavily pre-treated recurrent gynecologic cancer patients who had received a median of 5 prior therapies. However, overall median PFS across all evaluable patients was only 5.8 months, 52% of patients did not achieve clinical benefit, and the use of LYMPHIR in this setting is investigational and not FDA-approved for solid tumors.

• · The Phase 1 study enrolled patients who received a median of 5 prior therapies; more than half had prior anti-PD-1/PD-L1 therapy.
• · Median duration of response (mDOR) not yet reached; only 1 of 5 partial responders had progressed at analysis date (80% continuing to benefit).
• · Among 10 patients achieving clinical benefit (48% of evaluable), mPFS was 20.5 months; 5 patients had PFS >20 months, 1 had >30 months PFS.
• · Overall mPFS across all 21 evaluable patients was 5.8 months, indicating the majority did not reach clinical benefit.
• · At the highest dose level, 16 serious adverse events occurred in 7 patients; 1 case of reversible Grade 3 capillary leak syndrome observed; no MTD reached.
• · LYMPHIR is FDA-approved only for relapsed/refractory Stage I-III CTCL (launched Dec 2025); the combination use in gynecologic cancers is investigational and not FDA-approved.
• · Management estimates the initial CTCL market for LYMPHIR exceeds $400M.

01-06-2026

iSpecimen Inc. (ISPC) received a delisting notice from Nasdaq on May 29, 2026, for failing to meet the minimum $2,500,000 stockholders' equity requirement under Listing Rule 5550(b)(1). As of March 31, 2026, the company reported stockholders' equity of only $814,038, and Nasdaq noted it also fails alternative listing standards. The company has 45 days to submit a compliance plan and may receive up to 180 days to regain compliance, but there is no assurance of acceptance or ultimate compliance.

• · The company's common stock continues to trade on Nasdaq Capital Market under symbol 'ISPC' with no immediate effect on listing or trading.
• · If Nasdaq rejects the compliance plan, iSpecimen has the opportunity to appeal to a Nasdaq Hearings Panel.

01-06-2026

McEwen Inc. filed an amendment to its 8-K to clarify that a $49.4 million dividend was received directly from its 49.0%-owned equity investee, Minera Santa Cruz S.A. (MSC), rather than indirectly through another investee. This dividend brings total dividends received from MSC in 2026 to $58.2 million, all generated from the San José silver-gold mine in Argentina. The filing is a clarifying correction with no other material changes.

• · The amendment corrects an inadvertent disclosure in the original 8-K filed May 22, 2026.
• · No other changes were made to the original filing besides minor conforming changes.
• · The dividend funds were generated from the operation of the producing San José silver-gold mine in Santa Cruz, Argentina.

01-06-2026

Greenwich LifeSciences, Inc. (GLSI) filed its Form 10-K annual report for the fiscal year ended [not specified], highlighting that it is a clinical-stage biopharmaceutical company with no current source of revenues and a history of substantial losses. The company expects to continue incurring substantial and increasing losses for the foreseeable future, primarily due to ongoing clinical trials for its lead product candidate, GP2, and other development activities. The filing also notes a material uncertainty about the company's ability to continue as a going concern, as it will need to raise substantial additional capital to fund operations.

• · The company has no source of revenues and may never generate revenues or achieve profitability.
• · The company expects to continue incurring substantial and increasing losses for the foreseeable future.
• · The filing includes a going concern warning, indicating the need to raise substantial additional capital.
• · The company's lead product candidate is GP2, an immunotherapy for breast cancer.
• · The company faces risks related to clinical trial success, regulatory approval, commercialization, and competition.
• · The company relies on third parties for clinical trials, manufacturing, and supply.
• · The company has not yet established sales, marketing, or distribution capabilities.
• · The company's ability to obtain regulatory approvals and market acceptance is uncertain.
• · The company is exposed to risks from operating in foreign countries, including regulatory, economic, and geopolitical factors.
• · Healthcare cost reduction legislation could materially adversely affect the company's business.

01-06-2026

USCB Financial Holdings, Inc. announced the retirement of William Turner, Executive Vice President and Chief Credit Officer of its subsidiary U.S. Century Bank, effective July 3, 2026. Sergio Garrido, currently Senior Vice President and Director of Credit Underwriting, will succeed him as Senior Vice President and Chief Credit Officer effective July 6, 2026. The filing contains no financial results or performance metrics.

• · William Turner's retirement is effective July 3, 2026; he will serve until that date.
• · Sergio Garrido's appointment as Senior Vice President and Chief Credit Officer is effective July 6, 2026.
• · The press release is attached as Exhibit 99.1.

01-06-2026

Newcleo Ltd., a private nuclear technology company, has raised over €1 billion from private investors and plans to list on the Nasdaq through a proposed business combination with SPAC NewHold Investment Corp III. Deputy CEO Elisabeth Rizzotti stated that for every euro received from the public sector, the company raised €34 from private investors, highlighting a significant private-market confidence. However, Rizzotti criticized European policy for lacking a clear funding plan, noting the EU's SMR Strategy provides only up to €200 million in guarantees by 2028 for all European projects, which she called insufficient compared to the company's own fundraising.

• · Newcleo is combining with SPAC NewHold Investment Corp III and will file a Registration Statement (including proxy/prospectus) with the SEC.
• · The company states US capital availability for innovation is 100 times greater than in Europe.
• · Rizzotti specifically praised the 'determination of the Italian government' on nuclear policy but called for similar courage in Brussels.
• · European bureaucracy was described as 'our real competitor' due to delays compared to Chinese and American competitors.

01-06-2026

Civista Bancshares, Inc. (CIVB) announced its participation at the Performance Trust Capital Connect Conference on June 2, 2026, where its executive leadership team will discuss banking trends, strategic growth initiatives, and the company's long-term outlook. The company furnished its First Quarter 2026 Investor Presentation as Exhibit 99.1. The filing is under Regulation FD and does not contain any financial results or period-over-period comparisons.

• · Civista Bank was founded in 1884 and operates 44 locations across Ohio, Southeastern Indiana, and Northern Kentucky.
• · Civista Bank offers commercial equipment leasing services nationwide through its Civista Leasing and Finance Division.
• · The company's common shares trade on the NASDAQ Capital Market under the symbol CIVB.

01-06-2026

OceanFirst Financial Corp. entered into a Registration Rights Agreement with WPGG 14 Orion Investments L.P. and WPFS II Orion Investments L.P. on June 1, 2026, in connection with the issuance of 9,574,639 shares of Voting Common Stock, 1,812 shares of Non-Voting Common Equivalent Stock, and warrants to purchase up to 11,386.64 shares of Non-Voting Common Equivalent Stock under an Investment Agreement dated December 29, 2025. The agreement grants the purchasers registration rights, including shelf registration, demand registration, and piggyback rights, with a minimum offering amount of $30 million. No financial performance data is provided in this filing.

• · The Registration Rights Agreement was entered into on June 1, 2026, and is effective as of that date.
• · The Investment Agreement was dated December 29, 2025.
• · The Certificate of Designations for Non-Voting Common Equivalent Stock was filed with the Delaware Secretary of State on May 29, 2026.
• · The agreement includes provisions for shelf registration, demand registration, piggyback registration, and block trades.
• · The Company will pay registration expenses, including reasonable fees of one nationally recognized law firm for the shareholders, capped at $225,000 for the first demand or underwritten shelf take-down and $100,000 for subsequent ones.
• · The agreement terminates on the date when no Registrable Securities remain outstanding.

01-06-2026

Pacira BioSciences announced that ISS has recommended stockholders vote FOR all three of Pacira's director nominees (Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans) and AGAINST all three nominees from dissident DOMA Perpetual Capital Management at the June 9, 2026 Annual Meeting. ISS noted Pacira's performance improved following the 5x30 strategy launch and that the board has been proactive in refreshment and governance, while DOMA's campaign was deemed unsubstantiated and lacking a compelling case for change. The filing does not include any financial performance data or quantitative metrics.

• · Annual Meeting date: June 9, 2026.
• · ISS noted the board separated CEO and chair roles upon appointing Frank Lee CEO in January 2024.
• · Seven out of 10 directors were either appointed or proposed for election since October 2023.
• · None of the dissident nominees have outside public board experience or experience participating in a strategic review.
• · Pacira's financial advisor is Goldman Sachs & Co. LLC; legal counsel is Perkins Coie LLP.
• · Proxy solicitor: D.F. King & Co., Inc. (toll-free 800-714-3310).

01-06-2026

Daré Bioscience, Inc. filed a DEFA14A supplement to its proxy statement for the 2026 annual meeting of stockholders to be held on June 11, 2026. The company engaged Okapi Partners LLC as an independent proxy solicitor for a fee of $15,000 plus expenses, and will bear the entire cost of soliciting proxies. No other changes were made to the original proxy statement.

• · The supplement is dated June 1, 2026, and supplements the proxy statement filed on April 28, 2026.
• · Okapi may solicit proxies in person, by telephone, or by other electronic means.
• · The company agreed to indemnify Okapi against certain liabilities related to its engagement.
• · Directors and employees may solicit proxies without additional compensation.
• · The company may reimburse brokerage firms, banks, dealers, and similar organizations for forwarding proxy materials to beneficial owners.

01-06-2026

Proficient Auto Logistics, Inc. (PAL) announced its participation in the William Blair Growth Stock Conference on June 2, 2026, and scheduled its Q2 2026 earnings release and conference call for August 10, 2026. The filing contains no financial results or period-over-period comparisons, only forward-looking statements and event announcements.

• · The company will host an investor conference call at 5:00 p.m. EDT on Monday, August 10, 2026, to discuss Q2 2026 results.
• · A press release disclosing Q2 2026 results will be issued at approximately 4:00 p.m. EDT on August 10, 2026.
• · Conference materials will be posted on the company's website at proficientautologistics.com under 'Investor Relations'.
• · The company operates one of the largest auto transportation fleets in North America, formed through the combination of seven operating companies, including two since its IPO in May 2024.

01-06-2026

Revelation Biosciences released an updated corporate presentation on June 1, 2026, which is attached as Exhibit 99.1 to this 8-K filing. The presentation is available on the company's website and is furnished, not filed, for SEC purposes.

• · The corporate presentation is dated June 1, 2026.
• · The presentation is furnished under Item 8.01 and is not deemed filed for SEC liability purposes.
• · The company's common stock trades on Nasdaq under symbol REVB, and its warrants trade under REVBW.

01-06-2026

Flushing Financial Corp. completed its merger with OceanFirst Financial Corp. on June 1, 2026. Each Flushing share was converted into 0.85 shares of OceanFirst common stock, with approximately 29.30 million OceanFirst shares issued as merger consideration. All Flushing directors and officers ceased their roles, and Flushing common stock was delisted from Nasdaq.

• · The merger was effected in two steps: first Merger Sub merged into Flushing, then Flushing merged into OceanFirst.
• · Flushing Bank will merge into OceanFirst Bank on June 2, 2026.
• · Outstanding Flushing RSU awards were either converted into OceanFirst RSU awards or cashed out.
• · Flushing common stock was suspended from trading after close on June 1, 2026, and will be delisted.
• · OceanFirst intends to file Form 15 to terminate Flushing's registration and reporting obligations.

01-06-2026

Jade Biosciences announced interim Phase 1 results for JADE101, an anti-APRIL monoclonal antibody for IgAN, showing mean IgA reductions of ~70% sustained at 12 weeks at the 700 mg dose, with a favorable safety profile and no serious adverse events. The company has an ongoing Phase 2 trial (JUNIPER) and plans to initiate a Phase 3 registrational trial in the first half of 2027. However, these are interim results from a small healthy volunteer study (n=32), and cross-study comparisons with competitors are limited by different trial designs.

• · JADE101 IgA-lowering potency estimated to be ~379-fold higher than sibeprenlimab and ~26-fold higher than povetacicept (cross-study comparison, no head-to-head data).
• · Half-life at steady state for JADE101 was ~8.7-fold longer than povetacicept and ~2.6-fold longer than sibeprenlimab.
• · Target-mediated drug disposition threshold with JADE101 estimated to be ~2.5-fold lower than sibeprenlimab.
• · No cases of hypogammaglobulinemia (IgG ≤3 g/L) observed.
• · No apparent impact of anti-drug antibodies on PK or PD.
• · Phase 2 JUNIPER trial is open-label, expected to enroll ~30 participants with two dosing intervals (Q8W and Q12W).
• · Interim Phase 2 data anticipated in 2027.
• · Phase 3 registrational trial planned for first half of 2027, pending FDA requirements.

01-06-2026

Rallybio Corporation (RLYB) and Avenzo Therapeutics announced a definitive merger agreement where Rallybio will acquire Avenzo, with the combined company operating as Avenzo Therapeutics and trading under ticker 'AVZO'. The transaction includes a concurrent oversubscribed private placement financing of $215 million from leading healthcare investors, expected to fund operations into late 2028. Pre-Transaction Rallybio equityholders will own approximately 2.8% of the combined company, while Avenzo equityholders (including financing participants) will own approximately 97.2%, reflecting a significant dilution for existing Rallybio shareholders.

• · The merger is expected to close in Q4 2026, subject to stockholder approvals and SEC registration statement effectiveness.
• · Rallybio intends to distribute substantially all of its pre-closing net cash to its pre-closing stockholders, and pre-closing Rallybio stockholders will receive contingent value rights (CVRs) for proceeds from the sale of REV102 program interests and other legacy assets.
• · Avenzo plans to present updated safety and efficacy results from AVZO-021 Phase 1 portion at the 2026 ASCO Annual Meeting later today.
• · Preliminary updated data for AVZO-023 in combination with fulvestrant from ORION-1 Phase 1 is expected in late 2026.
• · Preliminary updated data from AVENTINE-1 Phase 1 and initial data from BEACON-1 Phase 1 are expected in late 2026.
• · The combined company expects to fund operations into late 2028 and support advancement through multiple clinical milestones including updated Phase 1 data, initial combination data, and initiation of multiple Phase 2 studies.

01-06-2026

Edgewise Therapeutics announced the sale of sevasemten and its muscular dystrophy business to Servier for up to $2.65 billion, including $1.55 billion in upfront cash and up to $1.1 billion in milestones. The transaction strengthens Edgewise's balance sheet and refocuses the company on its cardiovascular pipeline (EDG-7500, EDG-15400, EDG-003). However, the company is divesting its late-stage muscular dystrophy program and will now rely entirely on earlier-stage cardiovascular assets, with no approved products or revenue to date.

• · Transaction unanimously approved by boards of both companies; expected to close in Q3 2026.
• · All Edgewise employees primarily supporting muscular dystrophy business will receive comparable offers at Servier.
• · Sevasemten has FDA Orphan Drug Designation for Becker and Duchenne, Rare Pediatric Disease Designation for Duchenne, Fast Track designations for both, and EMA Orphan Drug Designations for both.
• · GRAND CANYON pivotal cohort in Becker is fully enrolled with 175 participants, powered at >98% to show statistically significant difference vs placebo; top-line data expected Q4 2026.
• · Edgewise plans to report 12-week Part D data from CIRRUS-HCM Phase 2 trial of EDG-7500 in Q2 2026; Phase 3 initiation targeted for Q4 2026.
• · Edgewise remains on track to initiate a Phase 2 trial of EDG-15400 in HFpEF.
• · Upfront proceeds combined with existing cash expected to fully fund EDG-7500 development through potential approval.
• · Edgewise has no approved products and has not generated any revenue to date.

01-06-2026

Energy Transition Special Opportunities (formerly Climate Transition Special Opportunities SPAC I) announced that holders of its units sold in the IPO may elect to separately trade the underlying Class A ordinary shares and warrants, commencing June 4, 2026. The company is a blank check company targeting climate transition, specialty finance, renewable energy, and regenerative agriculture sectors. No financial results or business combination were announced.

• · The company changed its name from Climate Transition Special Opportunities SPAC I to Energy Transition Special Opportunities on September 15, 2025.
• · The registration statement for the securities became effective on May 14, 2026.
• · Units not separated will continue to trade on NYSE under symbol 'ETSS U'.
• · Separated Class A ordinary shares will trade under 'ETSS' and warrants under 'ETSS WS'.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new financial accounting standards.

01-06-2026

Coca-Cola Europacific Partners plc filed a Form 6-K disclosing multiple PDMR transactions. Chief Commercial Officer Stephen Lusk sold 3,175 ordinary shares at $94.70 each for a total of ~$300,679. Separately, CFO Edward Walker, General Counsel Svetlana Walker, Chief Strategy Officer Leendert den Hollander, and Chief Customer Service and Supply Chain Officer Stephen Moorhouse each acquired fractional shares under the UK Share Plan at a weighted average price of ~$50.05 per share. The filing does not include any financial results or period-over-period comparisons.

• · All transactions were executed on The Nasdaq Stock Market LLC (XNAS).
• · Stephen Lusk's sale was an open-market sale, while the other PDMRs' acquisitions were pursuant to the UK Share Plan.
• · The UK Share Plan acquisitions included shares at $0.00 price, indicating a matching or award component.
• · Svetlana Walker had two separate transactions on May 19, 2026: one under the UK Share Plan and one additional purchase of 2.17382 shares at $91.7645 each.

01-06-2026

Bogota Financial Corp. (BSBK) announced a merger agreement with GSL Savings Bank, expected to close in H2 2026, which will increase consolidated assets from ~$877.2M to ~$1.0B. The transaction is unanimously approved by both boards and is projected to be accretive to 2026 net income, EPS, and fully converted tangible book value. However, the merger is subject to regulatory approvals and customary closing conditions, with risks including integration challenges, higher-than-expected costs, and potential business disruption.

• · Frank Giancola will become Executive Vice President and Chief Operating Officer of Bogota post-merger.
• · Bogota Financial will issue shares of common stock to the MHC equal to the fair value of GSL as determined by independent appraisal.
• · Bogota Savings Bank has served customers since 1893; GSL Savings Bank was founded in 1907.
• · The merger is expected to be accretive to fully converted tangible book value.
• · The transaction is subject to customary closing conditions including regulatory approvals.

01-06-2026

BV Financial, Inc. announced on June 1, 2026, that its Board of Directors elected Timothy L. Prindle as Chairman of the Board, in addition to his existing roles as President and CEO. Concurrently, the independent directors elected William B. Crompton, III as Lead Independent Director to ensure strong independent oversight. The combined Chairman/CEO role was determined to be in the best interests of the Company and its stockholders, reflecting Mr. Prindle's leadership and the Company's strong performance.

• · The Board reviews its leadership structure annually.
• · The Lead Independent Director meets with independent directors without management present and provides input on meeting agendas.
• · Mr. Prindle was elected Chairman due to his extensive knowledge of the Company and its markets, leadership qualities, and ability to oversee strategy implementation.

01-06-2026

Financial Solutions Advisory Group, Inc. filed its 13F-HR for the quarter ended March 31, 2026, reporting a total of 174 equity holdings with a combined market value of approximately $723.4 million. The portfolio is heavily weighted towards ETFs and large-cap stocks, with top holdings including SPDR S&P 500 ETF Trust ($103.1M), Schwab U.S. Large-Cap ETF ($70.8M), and iShares Core 1-5 Year USD Bond ETF ($57.4M). The filing shows a diversified approach across sectors, but no prior period comparison is available to assess changes.

• · The filing was signed by Mark C. Soehn, Co-Founder/CCO/Principal, on June 1, 2026.
• · The largest single holding by market value is SPDR S&P 500 ETF Trust at $103,132,742 (3,534,364 shares).
• · The portfolio includes a significant allocation to fixed-income ETFs, such as iShares Core 1-5 Year USD Bond ETF ($57.4M) and Invesco BulletShares ETFs.
• · Notable individual stock holdings include Broadcom Inc ($13.4M), Apple Inc ($3.3M), and Microsoft Corp ($3.9M).
• · The filing does not include any prior period comparison, so no quarter-over-quarter changes can be assessed.

01-06-2026

RCI Hospitality Holdings, Inc. (RICK) received notice from Nasdaq on May 29, 2026, that it has regained compliance with Listing Rule 5250(c)(1) following the filing of its Form 10-Q for the quarter ended March 31, 2026, on May 28, 2026. The company had previously been notified on May 20, 2026, that it was not in compliance with the periodic filing requirement. This resolution closes the matter with Nasdaq.

• · The initial non-compliance notice was issued on May 20, 2026.
• · The compliance notice was received on May 29, 2026.
• · The Form 10-Q for the fiscal quarter ended March 31, 2026, was filed on May 28, 2026.

01-06-2026

Via Renewables, Inc. announced on June 1, 2026, the redemption of 1,884,935 shares of its 8.75% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock at a price of $25.00 per share, plus any declared and unpaid dividends up to the redemption date of June 30, 2026. The redemption is part of the company's capital management strategy and involves a total principal amount of approximately $47.1 million.

• · The redemption date is set for June 30, 2026.
• · The redemption includes any declared and unpaid dividends on the shares up to (but not including) the redemption date.
• · The filing includes a press release (Exhibit 99.1) and a notice of redemption (Exhibit 99.2).
• · The Series A Preferred Stock has a par value of $0.01 per share and trades under the symbol VIASP on the NASDAQ Global Select Market.

01-06-2026

HPE reported record Q2 FY2026 revenue of $10.7B, up 40% YoY, with GAAP EPS of $0.44 (up $1.26 YoY) and non-GAAP EPS of $0.79 (up $0.41 YoY), both above guidance. However, Networking operating profit margin declined to 21.6% from 25.0% YoY, and Corporate Investments and Other segment remained unprofitable with a -3.2% margin. The company raised its full-year FY2026 guidance and introduced a FY2027 growth framework, while also completing the sale of its remaining 19% stake in H3C for $1.357B in cash.

• · GAAP gross margin of 36.5% was up 810 bps YoY and 60 bps sequentially.
• · Non-GAAP gross margin of 36.9% was up 750 bps YoY and 30 bps sequentially.
• · Networking segment revenue breakdown: Campus & Branch $1.3B (+50.2% YoY), Data Center Networking $320M (+233.3% YoY), Security $273M (+155.1% YoY), Routing $775M (vs $1M prior year).
• · Cloud & AI segment revenue breakdown: Server $5.5B (+32.7% YoY), Storage $1.2B (+2.4% YoY), Financial Services $0.9B (+5.6% YoY).
• · Cash flow from operations increased by $1.9B YoY to $1.4B.
• · Free cash flow increased by $1.8B YoY to $0.9B.
• · Dividend declared: $0.1425 per share, payable July 15, 2026 to holders of record June 16, 2026.
• · Q3 FY2026 revenue guidance: $11.5B to $12.1B.
• · FY2026 full-year revenue growth guidance raised to 29%-33%.
• · FY2026 Networking segment revenue growth guidance raised to 72%-75%.
• · FY2026 GAAP diluted net EPS guidance raised to $2.42-$2.52; non-GAAP to $3.35-$3.45.
• · FY2026 free cash flow guidance raised to at least $3.5B.
• · FY2027 framework: revenue growth 8%-12%, non-GAAP EPS growth 12%-16%, non-GAAP operating margin 12%-16%, free cash flow at least $4.5B.
• · H3C divestiture completed May 28, 2026; cash proceeds of ~$1.357B received.

01-06-2026

Principal Financial Group issued $400M of 5.300% Senior Notes due 2037, fully guaranteed by Principal Financial Services, Inc. The notes were sold under an effective shelf registration statement and closed on June 1, 2026. No period-over-period comparisons are available as this is a debt issuance event.

• · The notes were issued under the Senior Indenture dated May 21, 2009, as supplemented by the Eighteenth Supplemental Indenture dated June 1, 2026.
• · The underwriting agreement was dated May 27, 2026, with BofA Securities, Goldman Sachs, and J.P. Morgan as representatives.
• · The shelf registration statement (File Nos. 333-293726 and 333-293726-01) became effective on February 25, 2026.

01-06-2026

IDEAYA Biosciences presented complete positive primary analysis data from the registrational Phase 2/3 OptimUM-02 trial at ASCO 2026, demonstrating the darovasertib combination significantly improved median PFS (6.9 vs 3.1 months, HR:0.42, p<0.0001) and showed a 58% risk reduction in disease progression versus investigator's choice in first-line HLA*A2:01 negative metastatic uveal melanoma. The company announced the FDA agreed to review its NDA under Real-Time Oncology Review, with NDA filing expected to complete in H2 2026, and plans to seek accelerated approval. However, overall survival data remains immature, grade 3/4 TRAEs were slightly higher in the darovasertib arm (40.6% vs 37.0%), and median dose intensity of crizotinib was relatively low at 77.1%.

• · Data cutoff date was January 23, 2026; median follow-up time was 7.4 months.
• · The primary endpoint for accelerated approval is median PFS by BICR; the Phase 3 primary endpoint is OS (immature).
• · Darovasertib/ICT randomization ratio was 2:1 (210 vs 103).
• · Median duration of response was 6.8 months (BICR) and 6.8 months (investigator), with 95% CI of (5.5, 11.3) and (4.8, 9.7) respectively.
• · Most common Grade 3/4 TRAEs for darovasertib combination: diarrhea (10.0%), syncope (7.1%), hypotension (3.8%).
• · Most common Grade 3/4 TRAEs for ICT: elevated ALT (7.0%), elevated AST (7.0%), diarrhea (6.0%), hepatitis (5.0%), colitis (4.0%).
• · Treatment-related serious adverse events: 9.2% (darovasertib combination) vs 25.0% (ICT).
• · The company completed its first pre-submission to FDA in May 2026 and expects to complete NDA filing in H2 2026.
• · NDA is being reviewed under the FDA Oncology Center of Excellence Real-Time Oncology Review program.
• · The trial enrolled 1L HLA*A2:01 negative metastatic uveal melanoma patients only.

01-06-2026

Hudson Pacific Properties, Inc. held its Annual Meeting on May 28, 2026, where all seven director nominees were elected, Ernst & Young LLP was ratified as the independent auditor for 2026, and an advisory resolution on executive compensation was approved. All votes passed with majority support, though director Andrea L. Wong received a notable 2,396,759.79 against votes, indicating some shareholder dissent.

• · Broker non-votes totaled 4,953,965.00 across all director elections and the executive compensation proposal.
• · The ratification of Ernst & Young as auditor received 47,411,514.68 shares in favor, with no broker non-votes.
• · The advisory executive compensation resolution passed with 41,108,058.91 shares in favor and 2,103,252.00 against.
• · Director Andrea L. Wong received 39,913,106.88 for votes, 2,396,759.79 against, and 941,569.00 abstentions, the highest opposition among nominees.

01-06-2026

Ares Commercial Real Estate Corp (ACRE) held its 2026 Annual Meeting on May 27, 2026, where stockholders elected two Class II directors (William S. Benjamin and Caroline E. Blakely), ratified Ernst & Young LLP as independent auditor for FY2026, and approved on a non-binding advisory basis the compensation of named executive officers. All proposals passed, though the advisory vote on executive compensation received a notable 11.2% against votes (2,518,989 out of 22,651,394 votes cast), indicating some shareholder dissent.

• · Broker non-votes totaled 17,249,325 for both director elections and the executive compensation proposal, representing a significant portion of shares not voted on those items.
• · Auditor ratification received 36,662,962 votes for, 328,926 against, and 2,908,831 abstentions, with no broker non-votes.
• · The advisory vote on executive compensation had 19,848,823 votes for, 2,518,989 against, and 283,582 abstentions.